In 2016, more than 2300 lung transplants were performed in the United States, and approximately 2700 candidates were added to the wait-list. 1 Clinical outcomes after lung transplantation lag behind those achieved with transplantation of other solid organs, with average 5-year survival of 55%. 1 Despite this, lung transplantation is a relatively understudied area of clinical research, and few prospective randomized trials are conducted in lung transplantation. In June 2017, the National Heart, Lung, and Blood Institute (NHLBI) and American Association for Thoracic Surgery (AATS) co-sponsored a workshop designed to bring participants together to summarize the current state of the science in adult lung transplantation, identify knowledge gaps, and determine priorities in clinical lung transplant research that could be addressed in the near future. Workshop topics were initially drafted by the AATS with input from the International Society for Heart and Lung Transplantation (ISHLT), and then finalized by the NHLBI and AATS leadership. Workshop participants included leaders in lung transplantation with specific expertise in thoracic surgery, pulmonary medicine, and bioethics. Although all present acknowledged that chronic lung allograft From the